白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2014年
1期
33-37
,共5页
白血病,髓样,急性%沙利度胺%抗肿瘤联合化疗方案
白血病,髓樣,急性%沙利度胺%抗腫瘤聯閤化療方案
백혈병,수양,급성%사리도알%항종류연합화료방안
Leukemia,myeloid,acute%Thalidomide%Antineoplastic combined chemotherapy protocols
目的 评价沙利度胺联合CAG方案治疗老年急性髓系白血病(AML)患者的临床疗效及安全性.方法 对51例初治的老年AML患者进行前瞻性研究,采用简单随机分组法分为沙利度胺联合CAG方案治疗组26例、CAG方案单用对照组25例,评估临床疗效及患者不良反应.结果 诱导缓解治疗2个周期后,治疗组完全缓解(CR)率为61.5％(16/26),对照组为48.0％(12/25),两组差异无统计学意义(P=0.404).治疗组1年CR率为53.8％(14/26),对照组为24.0％(6/25)(P=0.045);治疗组2年CR率为42.3％(11/26),对照组为12.0％(3/25) (P=0.027);治疗组1年及2年生存率分别为73.1％和46.1％,对照组分别为52.0％和24.0％;随访2年,治疗组中位生存时间为22个月,对照组为13个月,差异有统计学意义(P=0.018).两组患者诱导死亡率及血液学不良反应发生率差异无统计学意义;但治疗组恶心、呕吐明显减轻,与对照组相比差异有统计学意义(P=0.025).结论 沙利度胺联合CAG方案治疗老年AML患者,疗效理想,患者不良反应轻,值得进一步研究及临床应用.
目的 評價沙利度胺聯閤CAG方案治療老年急性髓繫白血病(AML)患者的臨床療效及安全性.方法 對51例初治的老年AML患者進行前瞻性研究,採用簡單隨機分組法分為沙利度胺聯閤CAG方案治療組26例、CAG方案單用對照組25例,評估臨床療效及患者不良反應.結果 誘導緩解治療2箇週期後,治療組完全緩解(CR)率為61.5％(16/26),對照組為48.0％(12/25),兩組差異無統計學意義(P=0.404).治療組1年CR率為53.8％(14/26),對照組為24.0％(6/25)(P=0.045);治療組2年CR率為42.3％(11/26),對照組為12.0％(3/25) (P=0.027);治療組1年及2年生存率分彆為73.1％和46.1％,對照組分彆為52.0％和24.0％;隨訪2年,治療組中位生存時間為22箇月,對照組為13箇月,差異有統計學意義(P=0.018).兩組患者誘導死亡率及血液學不良反應髮生率差異無統計學意義;但治療組噁心、嘔吐明顯減輕,與對照組相比差異有統計學意義(P=0.025).結論 沙利度胺聯閤CAG方案治療老年AML患者,療效理想,患者不良反應輕,值得進一步研究及臨床應用.
목적 평개사리도알연합CAG방안치료노년급성수계백혈병(AML)환자적림상료효급안전성.방법 대51례초치적노년AML환자진행전첨성연구,채용간단수궤분조법분위사리도알연합CAG방안치료조26례、CAG방안단용대조조25례,평고림상료효급환자불량반응.결과 유도완해치료2개주기후,치료조완전완해(CR)솔위61.5％(16/26),대조조위48.0％(12/25),량조차이무통계학의의(P=0.404).치료조1년CR솔위53.8％(14/26),대조조위24.0％(6/25)(P=0.045);치료조2년CR솔위42.3％(11/26),대조조위12.0％(3/25) (P=0.027);치료조1년급2년생존솔분별위73.1％화46.1％,대조조분별위52.0％화24.0％;수방2년,치료조중위생존시간위22개월,대조조위13개월,차이유통계학의의(P=0.018).량조환자유도사망솔급혈액학불량반응발생솔차이무통계학의의;단치료조악심、구토명현감경,여대조조상비차이유통계학의의(P=0.025).결론 사리도알연합CAG방안치료노년AML환자,료효이상,환자불량반응경,치득진일보연구급림상응용.
Objective To evaluate the clinical efficacy and safety for the CAG regimen combined with thalidomide in elderly patients with acute myelogenous leukemia (AML).Methods 51 untreated elderly cases with AML were randomly divided into treatment group (treated with CAG regimen combined with thalidomide,26 cases) and control group (treated with CAG regimen alone,25 cases),and the clinical efficacy and safety were observed.Results After 2 cycles of treatment,the complete remission (CR) rates of treatment group and control group were 61.5 ％ (16/26) and 48.0 ％ (12/25) respectively,the difference was not significant (P =0.404).With regard to prostecdtive efficacy,the difference was markedly significant,1-year CR rates of treatment group and control group were 53.8 ％(14/26) and 24.0 ％ (6/25) respectively (P =0.045),and 2-year CR rates were 42.3 ％ (11/26) and 12.0 ％ (3/25) respectively (P =0.027).During the follow-up of 2 years,overall 1-and 2-year overall survival rates were 73.1％ and 46.1％ in treatment group versus 52.0 ％ and 24.0 ％ in control group.During the follow-up of 2 years,the estimated mean overall survival time in treatment group was 22 months and it was 13 months in control group (P =0.018).The induction mortality rates and myelosuppression showed no difference between the two groups.Compared with control group,the side effect rate of nausea and vomiting was significantly decreased in treatment group (P =0.025).Conclusion The CAG regimen combined with thalidomide is effective with little side effects for elderly AML,and is worthy of further study and clinic application.
